Dr. Wang on Future Research With CAR T-Cell Therapy in MCL

Video

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma (MCL). 

CAR T-cell therapy is a new ​therapeutic modality in MCL, so additional research is needed, says Wang.

In the phase 2 ZUMA-2 trial, it was discovered that certain cytokines are associated with efficacy and toxicity​, explains Wang. Moreover, future research efforts should aim to develop new measures that could enhance efficacy and minimize​ toxicity in these patients. 

As the ZUMA-2 trial was relatively small, larger studies are necessary to obtain further insight on​ the utility of minimal residual disease, as well as cytokine ​profiling, Wang concludes.

Related Videos
Rebecca Epperly, MD, a clinical investigator in the Department of Bone Marrow Transplantation & Cellular Therapy at St. Jude Children’s Research Hospital
Atul Malhotra, MD, PhD, on Treating Preterm Infants With Autologous Stem Cell Therapy
Uttam Rao, MD, MBA
Vivien Sheehan, MD, PhD, an associate professor of pediatrics at Emory University
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
© 2024 MJH Life Sciences

All rights reserved.